Recurrent Glioblastoma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Recurrent Glioblastoma Emerging Therapy and TPP Insights

Thelansis’s “Recurrent Glioblastoma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Recurrent Glioblastoma Overview

Recurrent glioblastoma remains one of the most difficult cancers to treat, with no universally established standard of care and median survival typically measured in months after recurrence. Its resistance reflects the blood-brain barrier, profound immunosuppression, and extreme cellular heterogeneity within tumors, which makes single-target therapies difficult to sustain. A distinctive approved option is tumor-treating fields (TTFields), delivered through a portable device using alternating electric fields to disrupt tumor-cell division. Although approved for recurrent disease, its pivotal randomized trial did not demonstrate a survival advantage over physician’s-choice chemotherapy. The most significant recent innovation has come from engineered cellular therapies, which have struggled in solid tumors because of poor persistence, an immunosuppressive microenvironment, and antigen heterogeneity. Newer approaches are addressing these barriers through multi-antigen targeting and alternative delivery methods, with early CAR-T studies showing tumor regression in some patients, although responses remain preliminary and sometimes transient. For stakeholders, recurrent glioblastoma illustrates the challenge of translating powerful cellular therapies into a highly heterogeneous, treatment-resistant solid tumor.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)